None listed
Conditions
Brief summary
The prevalence of cancer diagnosis is high and attributable to 30% of all deaths in Australia. There is a need for better treatment combined with reliable assessments of treatment effectiveness. This intervention study aims to assess the treatment effect of Electromagnetic Frequency (EMF) therapy for patients with cancer using the Circulating Tumour Cell (CTC) in cancer patients. Who is it for? You may be eligible for this study, if you have been diagnosed with cancer. Study details Patients will undergo an intial EMF session of 60-90 min to assess treatment effectiveness of the chosen patient-specific frequency program. Effectiveness will be assessed by blood tests measuring the number of Circulating Tumour Cells (CTC) before and 1 day after treatment. If successful, the patient will discuss with their health practitioner a 12 week treatment plan, which may involved twice weekly EMF sessions for 12 weeks. A follow-up CTC test at 3 months is scheduled to assess treatment effectiveness in the context of long-term clinical outcome. It is hoped, that this study will provide insight into the effectiveness of EMF therapy for cancer, with the aim to reduce CTC count, reduce tumour size and cancer spread, and improve symptoms and quality of life.
Interventions
Electro-Magnetic-Frequency Therapy (EMF) consists of a suite of low frequency waves (<25x10^6 Hz) – lower than those emitted by mobile phones (1x10^8 Hz) – specific to the cancer.
We will use the EMF device Spooky2 plus Phanotron plasma bulb or plasma tube, and a suite of frequencies specific to the patient's illness as per EMF/Rife catalogue ranging between 1 Hz to 3.5 MHz..
EMF therapy is adminstered by a EMF trained nurse, who will also monitor adherence to the therapy.
EMF waves are tra
Electro-Magnetic-Frequency Therapy (EMF) consists of a suite of low frequency waves (<25x10^6 Hz) – lower than those emitted by mobile phones (1x10^8 Hz) – specific to the cancer. We will use the EMF device Spooky2 plus Phanotron plasma bulb or plasma tube, and a suite of frequencies specific to the patient's illness as per EMF/Rife catalogue ranging between 1 Hz to 3.5 MHz.. EMF therapy is adminstered by a EMF trained nurse, who will also monitor adherence to the therapy. EMF waves are transmitted through the air whilst the patient is sitting closely (~10 cm-100cm) to the frequency emitting plasma tube. EMF sessions are typically of 60-90 min length, during which the patient can undertake some stationary relaxing activities, e.g. reading, writing, meditating, without using an electronic device A one-off EMF therapy session is scheduled initally, and treatment effectiveness assessed by 2x blood tests before and after the session. The patient will then discuss with their health practitioner a treatment program of 12 week duration, e.g. twice weekly sessions for 12 weeks.
Sponsors
AProf Dr Karin Ried
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
adults diagnosed with cancer at any stage of their cancer treatment, including patients undergoing active cancer treatment, and patients in remission as determined by pathology testing following completion of cancer treatment;
Exclusion criteria
patients with electronic implants, e.g. pacemaker, defibrillator, cochlear implant, ring-shaped metals in the body planning to introduce new treatments during the study period unable to commit to regular treatment sessions over a 3 month period unable to give consent
Outcome results
None listed